UNH shares plunge to $277 (-50%yr/-17%YTD) post-CEO crisis/legal beats; RJ/BofA/Bernstein PT upgrades; SCHD ETF bottom signal; CMS-driven surge to $310+
Key Questions
Why did UnitedHealth Group (UNH) shares plunge to $277?
UNH shares dropped to a 52-week low of $277-281, down 54% from the April 2025 high of $606, due to Medicare Advantage probes, CEO swap, rising costs, and litigation risks including DOJ investigations. The stock was also down 50% year-over-year and 17% year-to-date amid these challenges. This marked low volatility and positioned it as a potential bottom signal in the SCHD ETF.
What caused the recent surge in UNH shares to $310+?
Shares surged 10-11% to $307.80-310.47 over a 5-day streak, driven by a CMS boost from finalized Medicare Advantage rates and analyst upgrades including Bernstein's $411 PT, Raymond James $330, and BofA $337. This followed the plunge from regulatory and leadership issues. The rally aligned with bullish options activity and a Strong Buy rating on Koyfin.
What are the latest analyst price targets for UNH?
Recent upgrades include Bernstein at $411, Raymond James at $330, BofA at $337, with consensus targets around $358-370 implying 27-32% upside from recent levels. Seeking Alpha notes 67% upside potential, and Motley Fool debates 21x TTM/16x forward valuation. Analysts cite margin expansion and CMS tailwinds as key drivers.
What is the current valuation of UNH stock?
UNH trades at a $300B market cap with P/E 15.5 forward (13.8x), ROIC 19.6%, and 3.2% yield, considered 65% undervalued by some metrics. Motley Fool highlights debate on 21x TTM vs. 16x forward amid MCR 89% and DOJ risks. Koyfin rates it Strong Buy with RSI 30-63.7.
What risks are associated with UNH stock?
Key risks include ongoing MA probes, CEO transition, cost pressures, and litigation such as DOJ cases and Mangione trials in 2026. Medicare coding and denial scrutiny add overhang despite CMS boosts. Mixed 13F filings show Citadel increasing stakes while others sell.
How does the SCHD ETF relate to UNH's recent performance?
UNH, a top-10 holding in the SCHD ETF, hit lows signaling a potential bottom for the ETF. The stock's plunge and subsequent rally from $277 align with SCHD's dividend-focused strategy. Vanguard holds 8.72-9% of UNH.
What is the impact of the CMS boost on UNH?
The CMS Medicare Advantage rate finalization drove an 10-11% surge, with articles noting it as a vital tailwind ahead of Q1 earnings. It eases prior overhangs like the 0.09% hike fears. Combined with analyst upgrades, it supports targets up to $411.
Is UNH considered a buy after its decline?
Analysts like Seeking Alpha see margin expansion potential rating it Buy, with 67% upside and Strong Buy on Koyfin. Bullish options at $300/$350 and 13F buys from Citadel support recovery. However, litigation and regulatory risks persist into 2026.
Shares $307.73-310.47 (+10-11% 6-day streak from $277-281 52w low234/high606/low vol/$255-300B cap/P/E15.5-16x fwd/ROIC19.6%/yield3.13-3.2%) down 54% from $606 Apr'25 high on MA probes/CEO swap/costs/litigation risks; Motley Fool 21x TTM/16x fwd valuation debate amid MCR89%/DOJ; SCHD top10 bottom signal; cons $358-370 +27-32%/Koyfin $358 Strong Buy/RSI30-63.7/bull opts/65% undervalued/SA 67% upside/div bargain; Vanguard 8.72-9%; mixed 13Fs Citadel+244.9%/PTJ vs sells; Mangione trials 2026; poised for 100-day MA breakout.